Antioxidant approaches for the treatment of Alzheimers disease

Expert Review of Neurotherapeutics

Volumn 10, Issue 7, 2010, Pages 1201-1208

  Lee, Hyun Pil ^a   Zhu, Xiongwei ^a   Casadesus, Gemma ^a   Castellani, Rudy J ^b   Nunomura, Akihiko ^c   Smith, Mark A ^a   Lee, Hyoung Gon ^a   Perry, George ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d University of San Antonio   (United States)

Author keywords

Alzheimers disease; antioxidants; oxidative stress; therapeutics

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DIMEBON; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL PROTECTION; CHELATION; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; HUMANS; OXIDATIVE STRESS;

EID: 77954202499     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.74     Document Type: Review

References (99)

1. Cummings JL, Cole G. Alzheimer disease. JAMA 287, 2335-2338 (2002).
2. Alzheimer A. [An unusual disease of the cerebral cortex]. Zentralblatt fur Nervenkrankheiten 25, 1134 (1906).
3. Smith MA, Casadesus G, Joseph JA et al. Amyloid-b and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33, 1194-1199 (2002).
4. Lee HG, Perry G, Moreira PI et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med. 11, 164-169 (2005).
5. Lee HG, Zhu X, Nunomura A et al. Amyloid b: the alternate hypothesis. Curr. Alzheimer Res. 3, 75-80 (2006).
6. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid b-protein. J. Alzheimers Dis. 3, 75-80 (2001).
7. Ashford J W. APOE genotype effects on Alzheimer's disease onset and epidemiology. J. Mol. Neurosci. 23, 157-165 (2004).
8. Teter B. ApoE-dependent plasticity in Alzheimer's disease. J. Mol. Neurosci. 23, 167-179 (2004).
9. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275, 630-631 (1997).
10. Bentahir M, Nyabi O, Verhamme J et al. Presenilin clinical mutations can affect g-secretase activity by different mechanisms. J. Neurochem. 96, 732-742 (2006).
11. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
13. Perry G, Nunomura A, Hirai K et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic. Biol. Med. 33, 1475-1479 (2002).
14. Perry G, Castellani RJ, Hirai K et al. Reactive oxygen species mediate cellular damage in Alzheimer disease. J. Alzheimers Dis. 1, 45-55 (1998).
15. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11, 298-300 (1956).
16. Harman D, Eddy DE, Noffsinger J. Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants; possible mechanism. J. Am. Geriatr. Soc. 24, 203-210 (1976).
17. Smith MA, Sayre LM, Monnier VM et al Radical ageing in Alzheimer's disease. Trends Neurosci. 18, 172-176 (1995).
18. Schulz JB, Lindenau J, Sey fried J et al. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267(16), 4904-4911 (2000).
19. Smith MA, Harris PL, Sayre LM et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866-9868 (1997).
20. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev. 49, 618-632 (2005).
21. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004).
22. Manczak M, Anekonda TS, Henson E et al Mitochondria are a direct site of A b accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol Genet. 15, 1437-1449 (2006).
23. Reddy PH, Beal MF. Amyloid b, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14, 45-53 (2008).
24. Hirai K, Aliev G, Nunomura A et al Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21, 3017-3023 (2001).
25. Castellani R, Hirai K, Aliev G et al. Role of mitochondrial dysfunction in Alzheimer's disease. J. Neurosci. Res. 70, 357-360 (2002).
26. Wang X, Su B, Fujioka H et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fbroblasts from sporadic Alzheimer's disease patients. Am. J. Pathol. 173, 470-482 (2008).
27. Wang X, Su B, Siedlak SL et al. Amyloid-b overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fssion/fusion proteins. Proc. Natl Acad. Sci. USA 105, 19318-19323 (2008).
28. Du H, Guo L, Fang F et al. Cyclophilin D defciency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 14, 1097-1105 (2008).
29. Russell RL, Siedlak SL, Raina AK et al Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch. Biochem. Biophys. 370, 236-239 (1999).
30. Mastrogiacomo F, Bergeron C, Kish SJ. Brain a-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J. Neurochem. 61, 2007-2014 (1993).
31. Moreira PI, Siedlak SL, Wang X et al. Auto phagocytosis of mitochondria is prominent in Alzheimer disease. J. Neuropathol. Exp. Neurol. 66, 525-532 (2007).
32. Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J. Neuropathol. Exp. Neurol. 53, 508-512 (1994).
33. Yates CM, Butterworth J, Tennant MC et al. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J. Neurochem. 55, 1624-1630 (1990).
34. Sayre LM, Perry G, Harris PL et al. In situoxidative catalysis by neurofbrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 74, 270-279 (2000).
35. Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by b-amyloid. Brain Res. 799, 91-96 (1998).
36. Huang X, Atwood CS, Hartshorn MA et al. The Ab peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609-7616 (1999). (Pubitemid 29289332)
37. Nunomura A, Perry G, Pappolla MA et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964 (1999). (Pubitemid 29133374)
38. Ramassamy C, Krzywokowski P, Bastianetto S et al. Apolipoprotein E, oxidative stress and EGb 761 in Alzheimer's disease brain. In: Ginkgo Biloba Extract (EGb 761) Study: Lesson From Cell Biology. Packer L, Christen Y (Eds). Elsevier, Paris, France, 69-83 (1998).
39. Zhu X, Lee HG, Perry G et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta 1772, 494-502 (2007).
40. Zhu X, Raina AK, Perry G et al. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3, 219-226 (2004).
41. Zhu X, Castellani RJ, Takeda A et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Dev. 123, 39-46 (2001).
42. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52, 511-535 (1997).
43. Sims NR, Bowen DM, Allen SJ et al. Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem. 40, 503-509 (1983).
44. DeKosky ST, Harbaugh RE, Schmitt FA et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol. 32, 625-632 (1992).
45. Whitehouse PJ. Cholinergic therapy in dementia. Acta Neurol. Scand. Suppl. 149, 42-45 (1993).
46. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann. NY Acad. Sci. 920, 321-327 (2000).
47. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 15, 85-91 (2001).
48. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J. Neural. Transm. Suppl. 62, 181-187 (2002).
49. Parsons CG, Gruner R, Rozental J et al. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32, 1337-1350 (1993).
50. Misztal M, Frankiewicz T, Parsons CG et al. Learning defcits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur. J. Pharmacol. 296, 1-8 (1996).
51. Wenk GL, Danysz W, Roice DD. Theeffects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport 7, 1453-1456 (1996).
52. Zajaczkowski W, Quack G, Danysz W Infusion of (+)-MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296, 239-246 (1996).
53. Bruce AJ, Boling W, Kindy MS et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2, 788-794 (1996).
54. Melov S, Ravenscroft J, Malik S et al. Extension of life-span with superoxide dismutase/catalase mimetics. Science 289, 1567-1569 (2000).
55. Adams JD, Jr., Klaidman LK, Odunze IN et al. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfde, and vitamin E. Mol. Chem. Neuropathol. 14, 213-226 (1991).
56. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 344, 796-798 (1994).
57. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol. Bull. 31, 159-165 (1995).
58. Sung S, Yao Y, Uryu K et al. Early vitamin E supplementation in young but not aged mice reduces Ab levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 18, 323-325 (2004).
59. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, a-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336, 1216-1222 (1997).
60. Morris MC, Evans DA, Bienias JL et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287, 3230-3237 (2002).
61. Engelhart MJ, Geerlings MI, Ruitenberg A et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223-3229 (2002).
62. Gray SL, Anderson ML, Crane PK et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J. Am. Geriatr. Soc. 56(2), 291-295 (2008).
63. Isaac MG, Quinn R, Tabet N. Vitamin for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. 16(3), CD002854 (2008).
64. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352(23), 2379-2388 (2005).
65. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300(19), 2253-2262 (2008).
66. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006(3), 31372 (2006).
67. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta. 1762, 256-265 (2006).
68. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47, 629-656 (2007).
69. Cochemé HM, Kelso GF, James AM et al. Mitochondrial targeting of quinines: therapeutic implications. Mitochondrion S94-S102 (2007).
70. James AM, Cochemé HM, Smith RA et al. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem. 280, 21295-21312 (2005).
71. Salvemini D, Wang ZQ, Zweier JL et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 286, 304-306 (1999).
72. Filipovska A, Kelso GF, Brown SE et al. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic: insights into the interaction of ebselen with mitochondria. J. Biol. Chem. 280, 23113-23126 (2005).
73. Murphy MP, Echtay KS, Blaikie FH et al. Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from a-phenyl-N-tert-butylnitrone. J. Biol. Chem. 278(49), 48534-48545 (2003).
74. Zhao K, Zhao GM, Wu D et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 279(33), 34682-34690 (2004).
75. Massaad CA, Washington TM, Pautler RG et al. Over expression of SOD-2 reduces hippocampal superoxide and prevents memory defcits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 13576-13581 (2009).
76. Hayashi T, Shishido N, Nakayama K et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-p peptide. Free Radic. Biol. Med. 43, 1552-1559 (2007).
77. Nakamura M, Shishido N, Nunomura A et al. Three histidine residues of amyloid-p peptide control the redox activity of copper and iron. Biochemistry 46, 12737-12743 (2007).
78. Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits p-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676 (2001).
79. Crapper McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferoxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308 (1991).
80. McLachlan DR, Smith WL, Kruck TPA. Desferoxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther. Drug Monit. 15, 602-607 (1993).
81. Liu G, Men P, Harris PL et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 406, 189-193 (2006).
82. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol. 610, 123-144 (2010).
83. Doody RS, Gavrilova SI, Sano M et al. Effect of Dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372, 207-215 (2008).
84. Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantin on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull. Exp. Biol. Med. 136(5), 474-477 (2003).
85. +) channels. Bull. Exp. Biol. Med. 132(5), 1079-1083 (2001).
86. Bachurin SO, Shevtsova EP, Kireeva EG et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. NY Acad. Sci. 993, 334-344 (2003).
87. Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767 (2001).
88. Chan A, Paskavitz J, Remington R et al. Effcacy of a vitamin/ nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16 month caregiver extension. Am. J. Alzheimers Dis. Other Demen. 23(6), 571-585 (2009).
89. Risner ME, Saunders AM, Altman JF et al. Effcacy of rosiglitazone in a genetically defned population with mi ld-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254 (2006).
90. Iadecola C, Goldman SS, Harder DR et al. Recommendations of the National Heart, Lung, and Blood Institute working group on cerebrovascular biology and disease. Stroke 37, 1578-1581 (2006).
91. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem. Cell Biol., 122, 339-352 (2004).
92. Vasdev S, Gill V, Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem. Biophys. 49, 48-63 (2007).
93. Vaziri ND, Wang XQ, Oveisi F et al. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36, 142-146 (2000).
94. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and infammation in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2, 582-593 (2006).
95. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical signifcance? Hypertension 44, 248-252 (2004).
96. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: infammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146 (2004).
97. Hasnain BI, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? Cleve. Clin. J. Med. 71, 327-334 (2004).
98. Tribble DL. AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: emphasison vitamin C, vitamin E, and b-carotene: a statement for healthcare professionals from the American Heart Association. Circulation 99, 591-595 (1999).
99. Castellani RJ, Lee HG, Zhu X et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. 111, 503-509 (2006).